专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06414147B1 2-amino-9-alkylpurines: GABA brain receptor ligands 失效
标题翻译： 2-氨基-9-烷基嘌呤：GABA脑受体配体
公开(公告)号：US06414147B1
公开(公告)日：2002-07-02
申请号：US09470940
申请日：1999-12-22
申请人： Kevin S. Currie , Pamela Albaugh , Paul Chen
发明人： Kevin S. Currie , Pamela Albaugh , Paul Chen
IPC分类号： C07D47318
CPC分类号： C07D473/00 , C07D473/18 , C07D473/24
摘要： Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein: W is oxygen or sulfur; X is (un)substituted lower alkyl; or X is (un)substituted aryl or heteroaryl; Y is hydrogen or lower alkyl; Z is lower alkenyl, lower alkynyl, or (un)substituted lower alkyl; T is (un)substituted aryl or heteroaryl. The compounds are highly selective agonists, antagonists, or inverse agonists for GABAa brain receptors, or prodrugs of agonists, antagonists, or inverse agonists for GABAa brain receptors. Thus these compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, Down's Syndrome, overdose with benzodiazepine drugs, and for the enhancement of memory.
摘要翻译：公开了下式的化合物或其药学上可接受的无毒盐，其中：W是氧或硫; X是（un）取代的低级烷基; 或者X是（未）取代的芳基或杂芳基; Y是氢或低级烷基; Z是低级烯基，低级炔基或（未）取代的低级烷基; T是（未）取代的芳基或杂芳基。该化合物是高度选择性的激动剂，拮抗剂或GABAa脑受体的反向激动剂，或GABAa脑受体的激动剂，拮抗剂或反向激动剂的前药。因此，这些化合物可用于诊断和治疗焦虑症，睡眠和癫痫发作障碍，唐氏综合症，苯并二氮卓类药物过量以及增强记忆功能。

2. 发明授权

US07642267B2 Benzimidazole and pyridylimidazole derivatives 失效
标题翻译：苯并咪唑和吡啶基咪唑衍生物
公开(公告)号：US07642267B2
公开(公告)日：2010-01-05
申请号：US11942480
申请日：2007-11-19
申请人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
发明人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
IPC分类号： C07D471/04 , A61K31/437
CPC分类号： C07D401/04 , C07D233/20 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D473/00 , C07D491/08 , C07D491/10
摘要： This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I. The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
摘要翻译：本发明涉及苯并咪唑，吡啶基咪唑和相关的双环杂芳基化合物，所有这些可以由式I描述。本发明特别涉及以高选择性和高亲和力结合GABA A受体的苯并二氮杂位点的化合物。本发明还涉及包含这些化合物的药物组合物以及这些化合物在治疗某些中枢神经系统（CNS）疾病中的用途。公开了制备式I化合物的新方法。本发明还涉及式I的苯并咪唑，吡啶基咪唑和相关的双环杂芳基化合物与一种或多种其它CNS剂的组合用于增强其它CNS剂的作用。此外，本发明涉及使用这些化合物作为组织切片中GABA A受体定位的探针。

3. 发明授权

US07300945B2 Benzimidazole and pyridylimidazole derivatives 失效
标题翻译：苯并咪唑和吡啶基咪唑衍生物
公开(公告)号：US07300945B2
公开(公告)日：2007-11-27
申请号：US11179458
申请日：2005-07-12
申请人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
发明人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
IPC分类号： C07D471/04 , A61K31/437
CPC分类号： C07D401/04 , C07D233/20 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D473/00 , C07D491/08 , C07D491/10
摘要： This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed.This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
摘要翻译：本发明涉及苯并咪唑，吡啶基咪唑和相关双环杂芳基化合物，所有这些可以由式I描述。本发明特别涉及以高选择性和高亲和力结合GABA A的苯并二氮杂部位的化合物， / SUB>受体。本发明还涉及包含这些化合物的药物组合物以及这些化合物在治疗某些中枢神经系统（CNS）疾病中的用途。公开了制备式I化合物的新方法。本发明还涉及式I的苯并咪唑，吡啶基咪唑和相关的双环杂芳基化合物与一种或多种其它CNS剂的组合用于增强其它CNS剂的作用。此外，本发明涉及使用这些化合物作为组织切片中GABA A A受体定位的探针。

4. 发明申请

US20100267698A1 Benzimidazole and Pyridylimidazole Derivatives 审中-公开
标题翻译：苯并咪唑和吡啶基咪唑衍生物
公开(公告)号：US20100267698A1
公开(公告)日：2010-10-21
申请号：US12652435
申请日：2010-01-05
申请人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
发明人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
IPC分类号： A61K31/55 , C07D401/14 , A61K31/4439 , C07D403/06 , A61K31/4184 , A61K31/4196 , A61K31/41 , C07D413/14 , A61K31/4245 , C07D471/04 , A61K31/437 , C07D417/14 , A61K31/427 , C07D473/00 , A61K31/52 , C07D403/14 , A61K31/496 , A61K31/506 , A61K31/5377 , A61P25/22 , A61P25/24 , A61P25/18 , A61P25/00 , C12N5/079 , C12Q1/02
CPC分类号： C07D401/04 , C07D233/20 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D473/00 , C07D491/08 , C07D491/10
摘要： This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed.This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
摘要翻译：本发明涉及苯并咪唑，吡啶基咪唑和相关双环杂芳基化合物，所有这些可以由式I描述。本发明特别涉及以高选择性和高亲和力结合GABA A受体的苯并二氮杂位点的化合物。本发明还涉及包含这些化合物的药物组合物以及这些化合物在治疗某些中枢神经系统（CNS）疾病中的用途。公开了制备式I化合物的新方法。本发明还涉及式I的苯并咪唑，吡啶基咪唑和相关的双环杂芳基化合物与一种或多种其它CNS剂的组合用于增强其它CNS剂的作用。此外，本发明涉及使用这些化合物作为组织切片中GABA A受体定位的探针。

5. 发明申请

US20080227793A1 Benzimidazole and Pyridylimidazole Derivatives 失效
标题翻译：苯并咪唑和吡啶基咪唑衍生物
公开(公告)号：US20080227793A1
公开(公告)日：2008-09-18
申请号：US11942480
申请日：2007-11-19
申请人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
发明人： Guiying Li , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu , George P. Luke , Scott Mitchell , Martin Patrick Allen , Spiros Liras
IPC分类号： A61K31/496 , C07D403/06 , A61K31/4184 , C07D471/04 , G01N33/566 , A61P25/18 , A61P25/24 , C12N5/06 , A61K31/437 , C07D403/14
CPC分类号： C07D401/04 , C07D233/20 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D473/00 , C07D491/08 , C07D491/10
摘要： This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed.This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
摘要翻译：本发明涉及苯并咪唑，吡啶基咪唑和相关双环杂芳基化合物，所有这些可以由式I描述。本发明特别涉及以高选择性和高亲和力结合GABA A的苯并二氮杂部位的化合物， / SUB>受体。本发明还涉及包含这些化合物的药物组合物以及这些化合物在治疗某些中枢神经系统（CNS）疾病中的用途。公开了制备式I化合物的新方法。本发明还涉及式I的苯并咪唑，吡啶基咪唑和相关的双环杂芳基化合物与一种或多种其它CNS剂的组合用于增强其它CNS剂的作用。此外，本发明涉及使用这些化合物作为组织切片中GABA A A受体定位的探针。

6. 发明授权

US06916819B2 Benzimidazole and pyridylimidazole derivatives 失效
标题翻译：苯并咪唑和吡啶基咪唑衍生物
公开(公告)号：US06916819B2
公开(公告)日：2005-07-12
申请号：US10038069
申请日：2001-12-21
申请人： Guiying Li , John M. Peterson , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , Vinod Singh , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu
发明人： Guiying Li , John M. Peterson , Pamela Albaugh , Kevin S. Currie , Guolin Cai , Linda M. Gustavson , Kyungae Lee , Alan Hutchison , Vinod Singh , George D. Maynard , Jun Yuan , Ling Hong Xie , Manuka Ghosh , Nian Liu
IPC分类号： A61K31/415 , A61K31/4184 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/435 , A61K31/437 , A61K31/438 , A61K31/4439 , A61K31/454 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61P25/00 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , C07D233/20 , C07D233/54 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D473/00 , C07D491/08 , C07D491/10 , C07D491/113 , C07D403/12
CPC分类号： C07D401/04 , C07D233/20 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/06 , C07D413/14 , C07D417/04 , C07D417/06 , C07D417/14 , C07D471/04 , C07D473/00 , C07D491/08 , C07D491/10
摘要： This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed.This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
摘要翻译：本发明涉及苯并咪唑，吡啶基咪唑和相关双环杂芳基化合物，所有这些可以由式I描述。本发明特别涉及以高选择性和高亲和力结合GABA A的苯并二氮杂部位的化合物， / SUB>受体。本发明还涉及包含这些化合物的药物组合物以及这些化合物在治疗某些中枢神经系统（CNS）疾病中的用途。公开了制备式I化合物的新方法。本发明还涉及式I的苯并咪唑，吡啶基咪唑和相关的双环杂芳基化合物与一种或多种其它CNS剂的组合用于增强其它CNS剂的作用。此外，本发明涉及使用这些化合物作为组织切片中GABA A A受体定位的探针。

7. 发明授权

US09249123B2 Pyridinones/pyrazinones, method of making, and method of use thereof 有权
标题翻译：吡啶酮/吡嗪酮，制造方法及其使用方法
公开(公告)号：US09249123B2
公开(公告)日：2016-02-02
申请号：US13819864
申请日：2011-08-31
申请人： Kevin S. Currie , Xiaojing Wang , Wendy B. Young
发明人： Kevin S. Currie , Xiaojing Wang , Wendy B. Young
IPC分类号： A61K31/381 , A61K31/40 , A61K31/4015 , A61K31/425 , A61K31/435 , A61K31/495 , C07D401/14 , A61K31/497 , C07D401/10 , C07D403/14 , C07D413/14 , C07D487/04 , C07D495/04 , C07D513/04 , C07D519/00 , A61K31/4439 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/542 , A61K45/06 , C07D498/04
CPC分类号： C07D401/14 , A61K31/4439 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/542 , A61K45/06 , C07D401/10 , C07D403/14 , C07D413/14 , C07D487/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D519/00
摘要： Pyridone and pyrazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I的吡啶酮和吡嗪酮化合物包括可用于抑制Btk激酶和用于治疗免疫疾病如Btk激酶介导的炎症的立体异构体，互变异构体和其药学上可接受的盐。公开了使用式I化合物进行体外，原位和体内诊断以及哺乳动物细胞或相关病理学条件下的这些疾病的治疗的方法。

8. 发明授权

US08618107B2 Pyridone and aza-pyridone compounds and methods of use 有权
标题翻译：吡啶酮和氮杂 - 吡啶酮化合物及其使用方法
公开(公告)号：US08618107B2
公开(公告)日：2013-12-31
申请号：US13102720
申请日：2011-05-06
申请人： Antonio J. M. Barbosa , Peter A. Blomgren , Kevin S. Currie , Ravi Krishnamoorthy , Jeffrey E. Kropf , Seung H. Lee , Scott A. Mitchell , Daniel Ortwine , Aaron C. Schmitt , Xiaojing Wang , Jianjun Xu , Wendy Young , Honglu Zhang , Zhongdong Zhao , Pavel E. Zhichkin
发明人： Antonio J. M. Barbosa , Peter A. Blomgren , Kevin S. Currie , Ravi Krishnamoorthy , Jeffrey E. Kropf , Seung H. Lee , Scott A. Mitchell , Daniel Ortwine , Aaron C. Schmitt , Xiaojing Wang , Jianjun Xu , Wendy Young , Honglu Zhang , Zhongdong Zhao , Pavel E. Zhichkin
IPC分类号： A61K31/50 , A61K31/501 , C07D487/00
CPC分类号： C07D519/00 , A61K31/497 , A61K31/4985 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K31/551 , A61K45/06 , C07C69/65 , C07D209/52 , C07D471/14 , C07D487/04 , C07D495/04 , C07D498/04 , C07F5/04
摘要： Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：提供式I的吡啶酮和氮杂 - 吡啶酮化合物，包括其可用于抑制Btk激酶的立体异构体，互变异构体及其药学上可接受的盐，以及用于治疗免疫疾病如Btk激酶介导的炎症。公开了使用式I化合物进行体外，原位和体内诊断以及哺乳动物细胞或相关病理学条件下的这些疾病的治疗的方法。

9. 发明申请

US20130261103A1 PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF 有权
标题翻译：吡咯烷酮，制备方法及其使用方法
公开(公告)号：US20130261103A1
公开(公告)日：2013-10-03
申请号：US13819870
申请日：2011-08-31
申请人： Kevin S. Currie , Xiaojing Wang , Wendy B. Young
发明人： Kevin S. Currie , Xiaojing Wang , Wendy B. Young
IPC分类号： C07D403/14 , A61K31/501 , A61K31/553 , C07D487/04 , C07D513/04 , A61K31/549 , C07D519/00 , A61K45/06
CPC分类号： C07D403/14 , A61K31/501 , A61K31/549 , A61K31/553 , A61K45/06 , C07D487/04 , C07D495/04 , C07D513/04 , C07D519/00
摘要： Pyridazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I的哒嗪酮化合物包括可用于抑制Btk激酶和用于治疗免疫疾病如Btk激酶介导的炎症的立体异构体，互变异构体和其药学上可接受的盐。公开了使用式I化合物进行体外，原位和体内诊断以及哺乳动物细胞或相关病理学条件下的这些疾病的治疗的方法。

10. 发明授权

US08450321B2 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor 有权
标题翻译： 6-（1H-吲唑-6-基）-N- [4-（吗啉-4-基）苯基]咪唑并[1,2-A]吡嗪-8-胺或其药学上可接受的盐，为 SYK抑制剂
公开(公告)号：US08450321B2
公开(公告)日：2013-05-28
申请号：US13441441
申请日：2012-04-06
申请人： Scott A. Mitchell , Kevin S. Currie
发明人： Scott A. Mitchell , Kevin S. Currie
IPC分类号： A61K31/495
CPC分类号： C07D471/04 , C07D487/04 , C07D491/107 , C07D498/04 , C07D498/08 , C07D519/00
摘要： An imidazopyrazine having the structure or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.
摘要翻译：本文提供具有结构或其药学上可接受的盐的咪唑并嗪及其药物组合物。治疗患有某些对抑制Syk活性有作用的疾病和病症的患者的方法，其包括给予这些患者一定量的至少一种有效减少疾病或病症体征或症状的化学实体。还提供了用于确定样品中Syk激酶的存在或不存在的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式